A Congress Bag for Women’s Empowerment
International Women’s Day: ESMO supports women in South Africa to become autonomous workers.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
International Women’s Day: ESMO supports women in South Africa to become autonomous workers.
Fertility doctors in France have announced the birth of the first baby to be born to a cancer patient from an immature egg that was matured in the laboratory, frozen, then thawed and fertilised five years later.
ESMO is pleased to announce that Lillian L. Siu will receive the TAT 2020 Honorary Award for her contributions in the development of new anticancer drugs.
The platform in Europe devoted entirely to the development and use of the immunotherapies against cancer, will take place from 11-14 December in Geneva, Switzerland with thousand participants from all over the world.
SINGAPORE- The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study to be reported at the ESMO Asia Congress 2019.
SINGAPORE – Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019 Congress.
Over 3,500 medical professionals are convening for the three-day scientific and educational congress to drive progress and contribute to shaping the oncology roadmap in the Asia-Pacific region
The European Society for Medical Oncology has selected Prof. Thomas Gajewski to receive the 2019 ESMO Award for Immuno-Oncology.
New data have shown for the first time that targeted therapy can improve the outcome of patients diagnosed with advanced cholangiocarcinoma.
Targeting faulty DNA repair mechanisms in advanced castration resistant prostate cancer can slow progression and potentially improve survival, paving the way for a new approach to treatment of the most common form of cancer in men.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.